Key facts
- This page summarizes Dov Bergwerk's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 Nov 2026, 16:08.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
Footnote F2
Restricted share units were granted on November 10, 2026, with 2,358 vesting on each of November 10, 2027, November 10, 2028 and November 10, 2029, and 2,359 vesting on November 10, 2030.